Asset overview
Program snapshot
Target: Unknown
Cell type: Unknown
Indications: Cancer
Sponsor: Inge Marie Svane
Institution: Inge Marie Svane
Adoptive Cell Therapy
Autologous tumor-infiltrating lymphocytes
Autologous tumor-infiltrating lymphocytes is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Inge Marie Svane, with a possible patent signal linked through modality_match. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Phase1
Status: Completed
Trial count: 1
Active trials: 0
First posted: September 28, 2017
Last updated: October 26, 2024
Signal summary
IP and BD posture
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation2
IP linkage3
Licensing clarity2
Strategic interest0
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT03296137